Outcome of Board Meeting - Sale and Transfer of API Business of the Company Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform that, the Board of Directors of Jubilant Pharmova Limited (the 'Company') in its meeting held today i.e., June 12, 2025, at 03:00 P.M. and concluded at 03:28 p.m., inter-alia, considered and approved sale and transfer of the Active Pharmaceutical Ingredients (API) business of the Company ('Undertaking') on a slump sale basis to Jubilant Biosys Limited (JBL), a wholly-owned subsidiary company, engaged in providing drug discovery services to global Pharmaceutical and Biotech companies Allotment of Optionally Convertible Redeemable Non-Cumulative Preference Shares(OCRPS) by Jubilant Biosys Limited, a wholly owned subsidiary Company (As Per BSE Announcement Dated on:01.10.2025)